Logo

Publikacije (222)

Nazad
C. Silva, T. Avčin, H. Brunner

To propose a common nomenclature to refer to individuals who fulfill the American College of Rheumatology classification criteria for systemic lupus erythematosus (SLE) during childhood or adolescence.

E. Sen, M. Beresford, T. Avčin, A. Ramanan

Lupus anticoagulants (LA) were first detected in patients with systemic lupus erythematosus (SLE) in 1952 by Conley and Hartmann.1 They identified patients in whom the activated partial thromboplastin time (APTT) was prolonged and which did not correct on the addition of normal plasma. Although Conley and Hartmann's original description was in association with a haemorrhagic disorder, subsequent reports from the 1960s highlighted patients with thrombotic events in the presence of LA.2 The term ‘lupus anticoagulant’ was introduced by Feinstein and Rapaport in 1972.3 It has, however, caused some confusion because LA tend to be procoagulant in vivo, and most people who test positive for LA do not meet criteria for a diagnosis of SLE.4 LA are a subset of antiphospholipid antibodies (aPL) which also include anticardiolipin antibodies (aCL) and anti-β2 glycoprotein-I (anti-β2GPI) antibodies among others. The clinical significance of these antibodies is their association with venous or arterial thrombosis, or recurrent fetal loss. This association constitutes the antiphospholipid antibody syndrome (APS) for which there are revised classification criteria published in 2006.5 Some features not included in the classification criteria are associated with APS and are more commonly seen in children than adults. These include immune-mediated thrombocytopenia, haemolytic anaemia, migraine, chorea and epilepsy.6 This paper aims to highlight which children should be tested for LA, and the significance of LA if they are detected. LA are a mixture of different immunoglobulins (IgG and IgM) that bind to various protein-phospholipid complexes.4 Targets include β2GPI, prothrombin, protein C and S and factor XI among others.7 In common with other antibodies, LA are produced by B lymphocytes. In the context of SLE, there is a generalised increase in production of autoantibodies. The reasons for production of LA in other contexts are …

M. Kolnik, N. Toplak, M. Debeljak, T. Avčin

Aim: To assess the prevalence of MEFV mutations in Caucasian children with Henoch-Schonlein purpura (HSP) and to investigate a possible association between the two diseases in a population with presumably low incidence of familial Mediterranean fever (FMF). Methods: One hundred and two children diagnosed with HSP between January 2002 and February 2009 were included in the study. Clinical data were obtained from medical charts. Children were tested for 6 common MEFV mutations. To find out the carrier rate of mutations in MEFV gene in Slovenian population a control group of 105 apparently healthy adults was screened. Results: Heterozygous MEFV gene mutations were found in 6% of children with HSP and in 7% of apparently healthy adults. The most common allelic variants found in both groups were as follows: V726A in 5 participants, K695R in 4 participants, E148Q in 3 participants and M694V in 1 participant. No significant differences in HSP clinical picture between the group of children with and without mutations in MEFV were found. HSP patients with MEFV mutations were younger than patients without MEFV mutations. Conclusion: In contrast to previously published researches, MEFV mutations are not more frequent in children with HSP comparing to apparently healthy population and have no influence on the clinical presentation of HSP.

S. Čučnik, T. Kveder, A. Artenjak, Z. U. Gallova, J. Swadźba, J. Musial, T. Iwaniec, L. Stojanovich et al.

Antibodies against β2-glycoprotein I (anti-β2GPI) are one of the hallmarks of the antiphospholipid syndrome (APS). However, they are heterogenic regarding their epitope specificity, pathogenic mechanisms and their avidity. In the current study we present some outstanding issues about avidity of anti-β2GPI antibodies. Our results confirmed that high avidity anti-β2GPI are associated with thrombosis and APS, while in low avidity anti-β2GPI group non-APS (predominantly systemic lupus erythematosus) patients prevailed.

A. Mékinian, E. Lachassinne, P. Nicaise-Roland, L. Carbillon, M. Motta, E. Vicaut, C. Boinot, T. Avčin et al.

Objectives This study aimed to describe the long-term outcome and immunological status of children born to mothers with antiphospholipid syndrome, to determine the factors responsible for childhood abnormalities, and to correlate the child's immunological profile with their mothers. Methods A prospective follow-up of a European multicentre cohort was conducted. The follow-up consisted of clinical examination, growth data, neurodevelopmental milestones and antiphospholipid antibodies (APL) screening. Children were examined at 3, 9, 24 months and 5 years. Results 134 children were analysed (female sex in 65 cases, birth weight 3000±500 g, height 48±3 cm). Sixteen per cent had a preterm birth (<37 weeks; n=22), and 14% weighted less than 2500 g at birth (n=19). Neonatal complications were noted in 18 cases (13%), with five infections (4%). During the 5-year follow-up, no thrombosis or systemic lupus erythematosus (SLE) was noted. Four children displayed behavioural abnormalities, which consisted of autism, hyperactive behaviour, feeding disorder with language delay and axial hypotony with psychomotor delay. At birth lupus anticoagulant was present in four (4%), anticardiolipin antibodies (ACL) IgG in 18 (16%), anti-β2 glycoprotein-I (anti-β2GPI) IgG/M in 16 (15%) and three (3%), respectively. ACL IgG and anti-β2GPI disappeared at 6 months in nine (17%) and nine (18%), whereas APL persisted in 10% of children. ACL and anti-β2GPI IgG were correlated with the same mother's antibodies before 6 months of age (p<0.05). Conclusion Despite the presence of APL in children, thrombosis or SLE were not observed. The presence of neurodevelopmental abnormalities seems to be more important in these children, and could justify long-term follow-up.

N. Toplak, V. Šubelj, T. Kveder, S. Čučnik, K. Prosenc, A. Trampuš-Bakija, L. Todorovski, T. Avčin

OBJECTIVES Influenza vaccination in children with rheumatic diseases is often recommended, but not frequently performed. Our aim was to assess the safety and efficacy of annual influenza vaccination in a longitudinal follow-up study of an unselected group of children with juvenile idiopathic arthritis (JIA). METHODS Thirty-one children with stable JIA (10 boys, 21 girls, mean age 11.0 years) receiving various therapies and 14 children in a control group (10 boys, 4 girls, mean age 11.9 years) were vaccinated with the annual influenza vaccine Begrivac® 2008/2009. The children in both groups were followed for adverse events and infections 6 months after vaccination. Autoantibodies production and antibody titers against three vaccine viruses were determined in serial samples taken before, 1 and 6 months after vaccination. RESULTS Eleven (35%) children with JIA and 5 (36%) children in the control group reported short-term adverse events. A JIA flare was observed one month after vaccination in 4 (13%) patients, and in the following five months in 7 (23%) patients. The response to vaccination after one month was significant in the control and study groups as a whole, but not in a subgroup of 4 children receiving anti-TNF-α therapy. After six months, no significant differences in the protective titers against vaccine viruses among the patient and control groups were observed. Changes in the mean values of autoantibodies after vaccination were found only for IgG aCL in the JIA group. CONCLUSIONS No long-term adverse events were reported after influenza vaccination in JIA and control group. Thirty-five percent of children with JIA experienced flare of the disease after vaccination. Protective antibodies against at least 2 vaccine viruses 6 months after vaccination were detected in all patients.

Rina Mina, M. Klein‐gitelman, A. Ravelli, M. Beresford, T. Avčin, G. Espada, B. Eberhard, L. Schanberg et al.

To define inactive disease (ID) and clinical remission (CR) and to delineate variables that can be used to measure ID/CR in childhood‐onset systemic lupus erythematosus (cSLE).

S. Zitnik, Tina Vesel, T. Avčin, M. Šilar, M. Košnik, P. Korošec

To cite this article:Žitnik SEK, Vesel T, Avčin T, Šilar M, Košnik M, Korošec P. Monitoring honeybee venom immunotherapy in children with the basophil activation test. Pediatr Allergy Immunol 2011 Doi: 10.1111/j.1399‐3038.2011.01233.x

MohamedBabikirAbdelraheem, C. Abitbol, P. Acott, Piotr Adamczyk, I. Akil, S. Akman, R. Akuse, S. Al-Akash et al.

The antiphospholipid antibody syndrome (APS) is a multisystemic autoimmune disease characterized by thromboembolic events, pregnancy morbidity, hematologic, dermatologic, neurologic, and other manifestations in the presence of elevated titers of antiphospholipid antibodies (aPL). Antiphospholipid antibodies are a heterogeneous group of autoantibodies directed against negatively charged phospholipids or phospholipidbinding plasma proteins. The most relevant aPL for identifying patients at risk for immune-mediated thrombosis are anticardiolipin antibodies (aCL), antibodies against b2 glycoprotein I (anti-b2GPI) and lupus anticoagulant (LA). The classification criteria for APS were developed by consensus and designate patients who suffered from vascular thrombosis or pregnancy morbidity associated with the presence of aPL, detected on two or more occasions at least 12 weeks apart (>Table 160.1). These criteria were developed for classification of adult patients with APS and include pregnancy morbidity as a clinical criterion, which is not applicable for the pediatric population. A classification of ‘‘probable APS’’ has been given to patients with aPL that have non-criteria clinical features associated with APS such as livedo reticularis, thrombocytopenia, nephropathy, and neurologic manifestations. Catastrophic antiphospholipid antibody syndrome (CAPS) is a rare, life-threatening variant of APS, characterized by acute microvascular occlusive disease involving at least three organ systems in less than a week. Etiology The cause of APS remains unknown. It may occur as an isolated clinical entity (primary APS) or in association with autoimmune diseases, infections and malignancies. Primary, isolated APS accounts for approximately half of all pediatric patients with APS. The majority of cases associated with underlying autoimmune disease occur in patients with systemic lupus erythematosus (SLE) and lupus-like disease. Preceding or concomitant infections were found in approximately 10% of children with primary APS or APS associated with autoimmune disease. APS associated with malignancies is exceedingly rare in childhood and accounts for less than 1% of all pediatric APS cases. Epidemiology APS is considered the most common acquired hypercoagulation state of autoimmune etiology, and aPL were reported in up to 25% of unselected children with thrombosis. The average age of onset in 121 pediatric APS patients included in an international registry was 10.7 years with the female-to-male ratio 1.2:1. Children of all ethnic background have been affected with APS. Antiphospholipid antibodies can be found in a high percentage of children that do not experience thrombosis. SLE is the autoimmune disease in which aPL occurs in highest percentage, with the reported mean frequencies of 44% for aCL, 40% for anti-b2GPI, and 22% for LA, respectively. The estimated incidence of thromboembolic events in pediatric SLE patients with positive LAwas 54% and with positive aCL 22%. Lowlevels of aPL can be found in childrenwithout any underlying disorder. These naturally occurring aPL are usually transient and could be the result of previous infections or vaccinations that are common in the pediatric population. LA can be rarely found in apparently healthy children as an incidental finding of prolonged activated partial thromboplastin time (aPTT) in pre-operative coagulation screening. The risk of future thrombosis is exceedingly low in otherwise healthy children who were incidentally found to have positive aPL.

A. Pirrone, Gašper Markelj, E. Piscianz, A. Jeverica, E. Valencic, M. Debeljak, A. Tommasini, T. Avčin

In the last decades, the spectrum of primary immunodeficiency diseases (PIDs) has greatly widened, including disorders that can variably impair different immune functions. Although several case series have been published for each disorders, no data is available on how these changes have reflected in the clinical practice of pediatric departments. Aim of the study: Based on the analysis of registry data, we evaluated the distribution of diagnoses among different PID categories, the clinical features and diagnostic investigations at disease onset in two pediatric departments, namely in Slovenia and in Italy. Results: 136 patients have been diagnosed at the two centers, with a widespread distribution into different disease categories. Considering the 109 patients who were still alive at the last follow-up, prevalence of pediatric-onset-PID in our area was roughly estimated to be around 31 per million inhabitants. Diagnosis was genetically confirmed in 79 cases (58.1%), with 29 different genes found mutated. The most common presenting symptoms were: recurrent infections (52.2%), inflammatory manifestations (36.7%), specific syndromic features (30.8%), unusual infections (1.6%) and failure to thrive/growth retardation (22.8%). Treatments at follow-up include antimicrobials (20), hematopoietic stem cell transplantation (17), immunoglobulin replacement therapy (16), and immunosuppressants (9). Conclusions: A huge number of different PIDs are encountered in pediatric departments, often presenting with complex clinical pictures. Our results suggest that the identification of PID may be improved by a multidisciplinary approach, attaching importance not only to infections but also to other symptoms arising from a defective immune function.

Joshua Pendl, M. Hollander, S. Nelson, Wajeeha Yousaf, N. Ruperto, M. Beresford, M. Klein‐gitelman, M. Punaro et al.

Nema pronađenih rezultata, molimo da izmjenite uslove pretrage i pokušate ponovo!

Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više